Brief: Ibio Inc - On Track For Regulatory Submission For Ibio-600 In Q1 2026
07/04/2025 12:41
April 7 (Reuters) - iBio Inc IBIO.O: IBIO ANNOUNCES IBIO-600 NON-HUMAN PRIMATE DATA SHOWING EXTENDED HALF-LIFE AND MUSCLE GROWTH, AND INTERIM IN VIVO RESULTS FOR FIRST-IN-CLASS ACTIVIN E ANTIBODY, ADVANCING CARDIOMETABOLIC AND OBESITY PIPELINE IBIO INC - ON TRACK FOR REGULATORY SUBMISSION FOR IBIO-600 IN Q1 2026 Source text: ID:nGNX5nt8GC Further company coverage: IBIO.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on iBio
See all newsBrief: iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
Brief: Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update
Brief: Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron